CAJ | 학술논문

目的探讨体外诱导自体细胞因子诱导的杀伤细胞(CIK)治疗胃癌以无瘤生存为结局的相关因素.方法应用生物技术体外诱导自体细胞因子激活的杀伤细胞进行临床应用.选择1998年1月1日至2009年12月31日在苏州大学附属第三医院手术治疗并经病理诊断的胃癌病例181例.采用Kaplan-Meier及Log-rank检验比较化疗联合CIK细胞治疗组(CIK治疗组)和化疗组对胃癌无瘤生存的影响.结果对影响预后的重要因素如性别、年龄、胃癌部位、肿瘤大小、组织学类型、浸润深度、淋巴结转移、病理分级等因素进行分析,两组间差异无统计学意义；CIK治疗组胃癌患者的无瘤中位生存时间明显高于化疗组(x2=9.722,P＜0.01)；且生存时间和CIK细胞治疗次数呈正相关(x2=14.769,P＜0.01).结论 CIK细胞治疗可以显著延长胃癌患者的中位生存时间.
목적 탐토체외유도자체세포인자유도적살상세포(CIK)치료위암이무류생존위결국적상관인소.방법 응용생물기술체외유도자체세포인자격활적살상세포진행림상응용.선택1998년1월1일지2009년12월31일재소주대학부속제삼의원수술치료병경병리진단적위암병례181례.채용Kaplan-Meier급Log-rank검험비교화료연합CIK세포치료조(CIK치료조)화화료조대위암무류생존적영향.결과 대영향예후적중요인소여성별、년령、위암부위、종류대소、조직학류형、침윤심도、림파결전이、병리분급등인소진행분석,량조간차이무통계학의의；CIK치료조위암환자적무류중위생존시간명현고우화료조(x2=9.722,P＜0.01)；차생존시간화CIK세포치료차수정정상관(x2=14.769,P＜0.01).결론 CIK세포치료가이현저연장위암환자적중위생존시간.
Objective To study the related factors of autologous cytokine-induced killer (CIK) cell treatment in vitro and the disease-free suvival of gastric cancer patients.Methods Gastric cancer patients were treated with autologous cytokine-induced killer cells in vitro by biotechnology.181 cases of gastric cancer after surgical treatment and pathological diagnosis in the third affiliated hospital of Soochow University between January 1,1998 and December 31,2009 were selected in this study.The clinical efficacy of chemotherapy in combination with CIK biotherapy ( CIK treatment group) on the disease-free survival of gastric cancer patients compared to the chemotherapy alone (chemotherapy group) was evaluated by Kaplan-Meier survival analysis and Log-rank test.Results The difference was not statistically significant in sex,age,tumor location,tumor size,histological types,invasion depth,lymph node metastasis or pathological grade.The disease-free median survival time of gastric cancer patients was significantly longer in the CIK treatment group than in the chemotherapy group (x2 =9.722,P ＜0.01 ),and there was a positive correlation between the survival time and the times of CIK cell treatment (x2 =14.769,P ＜ 0.01 ).Conclusion CIK cell treatment can significantly prolong the median survival time of gastric cancer patients.